Insider Buying: Ekso Bionics (NASDAQ:EKSO) Major Shareholder Purchases $191,142.00 in Stock

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) major shareholder Daniel Asher bought 15,540 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were purchased at an average price of $12.30 per share, with a total value of $191,142.00. Following the transaction, the insider owned 270,432 shares of the company’s stock, valued at $3,326,313.60. The trade was a 6.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ekso Bionics Trading Down 9.1%

Shares of EKSO opened at $11.18 on Monday. The stock’s fifty day simple moving average is $8.30 and its 200-day simple moving average is $5.78. The firm has a market capitalization of $29.29 million, a PE ratio of -1.97 and a beta of 0.80. Ekso Bionics Holdings, Inc. has a 12-month low of $2.73 and a 12-month high of $13.27. The company has a quick ratio of 1.09, a current ratio of 1.66 and a debt-to-equity ratio of 0.11.

Institutional Investors Weigh In On Ekso Bionics

Several large investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new position in shares of Ekso Bionics during the third quarter worth $57,000. Shay Capital LLC acquired a new stake in Ekso Bionics during the 3rd quarter worth $67,000. Citadel Advisors LLC bought a new position in Ekso Bionics during the third quarter worth about $198,000. Geode Capital Management LLC grew its stake in Ekso Bionics by 68.9% in the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after acquiring an additional 10,281 shares during the period. Finally, Consolidated Portfolio Review Corp acquired a new position in Ekso Bionics in the third quarter valued at about $333,000. Institutional investors own 6.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on EKSO. Wall Street Zen raised shares of Ekso Bionics to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ekso Bionics in a research report on Monday, December 22nd. Finally, HC Wainwright downgraded Ekso Bionics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 31st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $10.50.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.